Intellia Therapeutics Inc (NTLA) Stock Price Down 3.5%
Shares of Intellia Therapeutics Inc (NASDAQ:NTLA) fell 3.5% during mid-day trading on Wednesday . The company traded as low as $19.21 and last traded at $19.39, with a volume of 100,419 shares trading hands. The stock had previously closed at $20.10.
A number of research firms have issued reports on NTLA. Zacks Investment Research upgraded shares of Intellia Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday. Wedbush restated an “outperform” rating and issued a $38.00 price objective on shares of Intellia Therapeutics in a research note on Tuesday, August 23rd. Jefferies Group restated a “buy” rating and issued a $33.00 price objective on shares of Intellia Therapeutics in a research note on Wednesday, August 17th. Leerink Swann upgraded shares of Intellia Therapeutics from a “market perform” rating to an “outperform” rating and set a $32.00 price objective for the company in a research note on Friday, August 5th. Finally, Credit Suisse Group AG initiated coverage on shares of Intellia Therapeutics in a research note on Tuesday, May 31st. They issued an “outperform” rating and a $39.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. Intellia Therapeutics has an average rating of “Buy” and a consensus price target of $35.50.
The stock’s market capitalization is $700.10 million. The firm has a 50 day moving average price of $19.47 and a 200 day moving average price of $22.93.
Intellia Therapeutics, Inc is a United States-based genome editing company focused on the development of curative therapeutics using a biological tool, CRISPR/Cas9 system. The Company’s CRISPR/Cas9 technology edits diseased genes in the human body through a single treatment course. It focuses on the therapeutic applications of CRISPR/Cas9 genome editing.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.